A Central Core consisting of the Program directors, an Administrative Assistant and a statistician will: Oversee the co-ordination of projects at Emory and the CDC; Facilitate the meeting of milestones; Oversee the budget; provide peptides and formulated DNAs; provide statistical support and a data management system; be responsible for the decisions as to which immunogens to take into macaque and human trials; provide contract support for GMP production of immunogens for phase 1 trials; participate in the preparation of the pre-IND and IND packages and take part in the pre-IND and IND meetings; oversee animal and phase 1 trial protocols; provide liquid nitrogen freezer space for macaque and human samples; communicate with program officers at the NIAID and provide annual reports. The work of the Central Core will be overseen by the Advisory committee consisting of Emory, CDC, and NIAID investigators.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Program Projects (P01)
Project #
5P01AI049364-02
Application #
6659160
Study Section
Special Emphasis Panel (ZAI1)
Project Start
2002-09-01
Project End
2003-06-30
Budget Start
Budget End
Support Year
2
Fiscal Year
2002
Total Cost
Indirect Cost
Name
Emory University
Department
Type
DUNS #
042250712
City
Atlanta
State
GA
Country
United States
Zip Code
30322
Pillai, Vinod Kumar Bhaskara; Kannanganat, Sunil; Penaloza-Macmaster, Pablo et al. (2011) Different patterns of expansion, contraction and memory differentiation of HIV-1 Gag-specific CD8 T cells elicited by adenovirus type 5 and modified vaccinia Ankara vaccines. Vaccine 29:5399-406
Pillai, Vinod Bhaskara; Hellerstein, Michael; Yu, Tianwei et al. (2008) Comparative studies on in vitro expression and in vivo immunogenicity of supercoiled and open circular forms of plasmid DNA vaccines. Vaccine 26:1136-41
Sadagopal, Shanmugalakshmi; Amara, Rama Rao; Kannanganat, Sunil et al. (2008) Expansion and exhaustion of T-cell responses during mutational escape from long-term viral control in two DNA/modified vaccinia virus Ankara-vaccinated and simian-human immunodeficiency virus SHIV-89.6P-challenged macaques. J Virol 82:4149-53
Nigam, Pragati; Earl, Patricia L; Americo, Jeffrey L et al. (2007) DNA/MVA HIV-1/AIDS vaccine elicits long-lived vaccinia virus-specific immunity and confers protection against a lethal monkeypox challenge. Virology 366:73-83
Lai, Lilin; Vodros, Dalma; Kozlowski, Pamela A et al. (2007) GM-CSF DNA: an adjuvant for higher avidity IgG, rectal IgA, and increased protection against the acute phase of a SHIV-89.6P challenge by a DNA/MVA immunodeficiency virus vaccine. Virology 369:153-67
Robinson, Harriet L; Sharma, Sunita; Zhao, Jun et al. (2007) Immunogenicity in macaques of the clinical product for a clade B DNA/MVA HIV vaccine: elicitation of IFN-gamma, IL-2, and TNF-alpha coproducing CD4 and CD8 T cells. AIDS Res Hum Retroviruses 23:1555-62
Liu, Jinyan; Hellerstein, Michael; McDonnel, Michael et al. (2007) Dose-response studies for the elicitation of CD8 T cells by a DNA vaccine, used alone or as the prime for a modified vaccinia Ankara boost. Vaccine 25:2951-8
Kannanganat, Sunil; Kapogiannis, Bill G; Ibegbu, Chris et al. (2007) Human immunodeficiency virus type 1 controllers but not noncontrollers maintain CD4 T cells coexpressing three cytokines. J Virol 81:12071-6
Velu, Vijayakumar; Kannanganat, Sunil; Ibegbu, Chris et al. (2007) Elevated expression levels of inhibitory receptor programmed death 1 on simian immunodeficiency virus-specific CD8 T cells during chronic infection but not after vaccination. J Virol 81:5819-28
Robinson, H L (2007) HIV/AIDS vaccines: 2007. Clin Pharmacol Ther 82:686-93

Showing the most recent 10 out of 20 publications